Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 ± tremelimumab vs platinum-based chemotherapy in first-line advanced NSCLC (Asia Pacific, Phase III)
TCTR20161027002Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2016
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on TCTR20161027002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20161027002.